A phase IIIB, randomized, active controlledopen-labeled study of Sunitinib 37,5 mg daily vs. Imatinib 800 mg daily in the treatment of patients with GIST who havehad PD while on 400 mg daily of Imatinib
(GIST, Gastrointestinale Stomatumoren, Peritoneum, Bauchrraum, Bauchfell)
